RNS Number : 3079Y
OKYO Pharma Limited
03 May 2023
 

3 May 2023

OKYO Pharma Limited

("OKYO" or "Company")

Result of General Meeting

The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that at the General Meeting ("GM") of the Company held earlier today all resolutions were duly passed.

The result of the poll, including the proxy voting, is as follows:

 

 

For

Against

Discretion

Withheld

 

For + discretion

Resolution

Description

Votes

% Votes Cast

Votes

% Votes Cast

Votes

% Votes Cast

Votes

Total Votes Cast (excl. Votes Withheld)

Votes

% Votes Cast

RES:001

SHARE CONSOLIDATION     

545,538,277

99.93

375,103

0.07

32,915

0.006

60,371

545,946,295

545,571,192

99.93

RES:002

DIRECTORS TO ALLOT SHARES

545,533,344

99.92

378,836

0.07

32,915

0.006

61,571

545,945,095

545,566,259

99.93

RES:003

PRE-EMPTION RIGHTS      

545,527,392

99.92

384,788

0.07

32,915

0.006

61,571

545,945,095

545,560,307

99.93

RES:004

AMENDMENT TO ARTICLES   

545,327,392

99.93

375,103

0.07

32,915

0.006

71,256

545,735,410

545,360,307

99.93

 

Further information on votes:

 

As at 2 May 2023, there were 1,658,792,349 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.

 

The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the GM itself, and will be available on the National Storage Mechanism,  https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

The result of poll and proxy voting will also be available on the Company's website, www.okyopharma.com.

 

Enquiries:

OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer

+44 (0)20 7495 2379

Investor Relations

Paul Spencer

+44 (0)20 7495 2379

 

Optiva Securities Limited
(Broker)           

Robert Emmet

+44 (0)20 3981 4173

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMBBGDUIUGDGXX